Mapi Pharma
We are a clinical stage pharmaceutical company, developing complex active pharmaceutical ingredients.
Focus
Our main focus is on developing long acting depot injectable drugs.
Programs
Our lead programs are GA Depot for treating various forms of MS and long acting Pregabalin (Lyrica®) for pain.
Latest News
Mapi Pharma Announces First Patient Recruited in Phase-I/II Study of Cariprazine Depot Once Monthly Injection
NESS ZIONA, Israel – Sep. 17, 2025 – Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on developing innovative long-acting depot injectable treatments, today provided an update on the clinical development program...
Mapi Pharma is Seeking New Depot Product Partnerships: Management to Participate in 7th Annual Evercore HealthCONx Conference
NESS ZIONA, Israel – Dec. 2, 2024 – Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot injectable treatments, will participate in the 7th Annual Evercore HealthCONx...